Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Blood (2022) 140 (Supplement 1): 5597–5599.

https://doi.org/10.1182/blood-2022-156110

Published: 2022

Journal Articles

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Amy L. Dunn, Yesim Dargaud, Yasmina L. Abajas, Manuel Carcao, Giancarlo Castaman, Adam Giermasz, Cédric Hermans, Magdalena D. Lewandowska, Johnny Mahlangu, Shannon L. Meeks, Wolfgang A. Miesbach, Michael Recht, Vanessa Salinas, Tammuella Chrisentery-Singleton, Hongying Wang, Ian S Mitchell, Guy Young

Blood (2022) 140 (Supplement 1): 8485–8488.

https://doi.org/10.1182/blood-2022-157343

Published: 2022

Journal Articles

Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial

Riten Kumar, Amy L. Dunn, Jane E. Schneiderman, Anne Gonzales, Vanessa Bouskill, Pamela Widener, Joseph Stanek, Fred G. Pluthero, Amanda Waller, Cristina Tarango, Sanjay Ahuja, Bryce A. Kerlin, Walter H. A. Kahr, Margaret L. Rand, David Lillicrap, Manuel Carcao

Blood (2022) 140 (10): 1156–1166.

https://doi.org/10.1182/blood.2022016146

Published: 2022

Includes: Supplemental data

Journal Articles

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Blood (2021) 138 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2021-147434

Published: 2021

Journal Articles

Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial

Blood (2021) 138 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2021-144508

Published: 2021

Journal Articles

Procoagulant Platelet Potential Is Inversely Correlated with Bleeding and Joint Disease in Severe Hemophilia A

Shawn M. Jobe, MD PhD, Amy L. Dunn, MD, Traci Leong, PhD

Blood (2018) 132 (Supplement 1): 1185.

https://doi.org/10.1182/blood-2018-99-117989

Published: 2018

Journal Articles

Unfractionated Heparin Use in Children: Clinical Outcomes in a Pediatric Cohort Managed Using an Anti-Factor Xa Based Nomogram

Surbhi Saini, MD, Katherine L Harsh, BS, Joseph R Stanek, MS, Sarah O'Brien, MD MSc, Amy L. Dunn, MD, Riten Kumar, MD MSc

Blood (2017) 130 (Supplement 1): 701.

https://doi.org/10.1182/blood.V130.Suppl_1.701.701

Published: 2017

Journal Articles

Increasing Ideal Coagulation Factor Dosing in the Pediatric Emergency Department: A Quality Improvement Study

Meghan Jackson, DO, Michael A Storey, PharmD, MS, Michael Dunn, MD, Amy L. Dunn, MD

Blood (2017) 130 (Supplement 1): 2093.

https://doi.org/10.1182/blood.V130.Suppl_1.2093.2093

Published: 2017

Journal Articles

Thrombin Generation in Patients with Severe Hemophilia A May Be Variable but Predictive of Response to Treatment

Ruchika Sharma, MD, Amy L. Dunn, MD, Shawn M. Jobe, MD PhD, Traci Leong, PhD, Shannon L. Meeks, MD

Blood (2017) 130 (Supplement 1): 3687.

https://doi.org/10.1182/blood.V130.Suppl_1.3687.3687

Published: 2017

Journal Articles

A Feasibility and Usability Study of a Nursing Orchestrated, Customized 3 Dimensional Virtual Reality Environment in Children with Hemophilia Undergoing Routine Intravenous Procedures

Amy L. Dunn, MD, Jeremy Patterson, Charmaine Biega, RN

Blood (2017) 130 (Supplement 1): 3691.

https://doi.org/10.1182/blood.V130.Suppl_1.3691.3691

Published: 2017

Journal Articles

Platelet-Dependent Thrombin Generation Is Correlated with Phenotypic Severity in Severe Hemophilia a

Amy L. Dunn, MD, Traci Leong, PhD, Shawn M. Jobe, MD PhD

Blood (2017) 130 (Supplement 1): 2355.

https://doi.org/10.1182/blood.V130.Suppl_1.2355.2355

Published: 2017

Journal Articles

Disease and Treatment Knowledge Deficits in Patients with Mild and Moderate Hemophilia May Impact Transition Readiness

Amy L. Dunn, MD, Linda Casto, MSW, LSIW, Pamela Widener, RN, BSN, Charmaine Biega, RN, Joseph R Stanek, MS

Blood (2017) 130 (Supplement 1): 5636.

https://doi.org/10.1182/blood.V130.Suppl_1.5636.5636

Published: 2017

Journal Articles

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Amy L. Dunn, MD, Alexis A. Thompson, MD MPH, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 3778.

https://doi.org/10.1182/blood.V128.22.3778.3778

Published: 2016

Journal Articles

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Eric S. Mullins, MD, Christine M. Knoll, MD, Amy L. Dunn, MD, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 1409.

https://doi.org/10.1182/blood.V128.22.1409.1409

Published: 2016

Journal Articles

Impact of Erythrocytapheresis on Endogenous Anticoagulants in Sickle Cell Disease

Ruchika Sharma, MD, Gary Woods, BS, MD, Susan E Creary, MD, Kan Hor, MD, Cody Young, MD, Christina Gallagher, RN, BSN, Emily McLain, RN, BSN, Trevorline Mongol, RN, BSN, Brooke Cohen, RN, BSN, Riten Kumar, MD MSc, Amy L. Dunn, MD

Blood (2015) 126 (23): 4590.

https://doi.org/10.1182/blood.V126.23.4590.4590

Published: 2015

Journal Articles

The Complete Type I VWD Cohort Of The Zimmerman Program For The Molecular and Clinical Biology Of VWD - Phenotypic Assignment, Mutation Frequency, and Bleeding Assessment

Robert R. Montgomery, MD, Pamela Christopherson, Daniel B. Bellissimo, Joan Cox Gill, Sandra L. Haberichter, Veronica H. Flood, MD, David Lillicrap, Anne C. Goodeve, Kenneth D Friedman, Thomas C. Abshire, Amy D. Shapiro, Margaret V. Ragni, Steven R. Lentz, Cindy A. Leissinger, Amy L. Dunn, Jeanne Lusher, Deborah Brown

Blood (2013) 122 (21): 332.

https://doi.org/10.1182/blood.V122.21.332.332

Published: 2013

Journal Articles

Epitope Specific Discrepancies Between Antibody Mediated Inhibition Of Recombinant Factor VIII and Plasma Derived Factor VIII Containing Von Willebrand Factor Affecting All Domains Of Factor VIII

Tami Livnat, PhD, Amy L. Dunn, MD, Shirley Azar-Avivi, Wallace Hunter Baldwin, B.S., Gili Kenet, MD, Shannon L. Meeks, MD

Blood (2013) 122 (21): 1089.

https://doi.org/10.1182/blood.V122.21.1089.1089

Published: 2013

Journal Articles

Long-Term Orthopedic Effects Of Delaying Prophylaxis In Severe Hemophilia A Until Age 6 Years: Results Of The Joint Outcome Study Continuation (JOSc)

Marilyn J. Manco-Johnson, MD, Michael L Manco-Johnson, MD, Taylor A Blades, BS, Sharon Funk, DPT, Heidi Lane, DPT, Kevin McRedmond, MD, Amy L. Dunn, MD, Michael Recht, MD, PhD, Amy D. Shapiro, MD, Leonard A. Valentino, MD, Deborah Brown

Blood (2013) 122 (21): 210.

https://doi.org/10.1182/blood.V122.21.210.210

Published: 2013

Journal Articles

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation

Veronica H. Flood, Kenneth D. Friedman, Joan Cox Gill, Sandra L. Haberichter, Pamela A. Christopherson, Brian R. Branchford, Raymond G. Hoffmann, Thomas C. Abshire, Amy L. Dunn, Jorge A. Di Paola, W. Keith Hoots, Deborah L. Brown, Cindy Leissinger, Jeanne M. Lusher, Margaret V. Ragni, Amy D. Shapiro, Robert R. Montgomery

Blood (2013) 121 (18): 3742–3744.

https://doi.org/10.1182/blood-2012-12-471672

Published: 2013

Journal Articles

Proteolytically Inactivatable Factor VIII is Less Immunogenic than Factor VIII in a Murine Hemophilia A Model.

Shannon Meeks, MD, Ernest T Parker, BS, Amy L. Dunn, MD, John F Healey, BS, Pete Lollar, MD

Blood (2009) 114 (22): 27.

https://doi.org/10.1182/blood.V114.22.27.27

Published: 2009

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial

Procoagulant Platelet Potential Is Inversely Correlated with Bleeding and Joint Disease in Severe Hemophilia A

Unfractionated Heparin Use in Children: Clinical Outcomes in a Pediatric Cohort Managed Using an Anti-Factor Xa Based Nomogram

Increasing Ideal Coagulation Factor Dosing in the Pediatric Emergency Department: A Quality Improvement Study

Thrombin Generation in Patients with Severe Hemophilia A May Be Variable but Predictive of Response to Treatment

A Feasibility and Usability Study of a Nursing Orchestrated, Customized 3 Dimensional Virtual Reality Environment in Children with Hemophilia Undergoing Routine Intravenous Procedures

Platelet-Dependent Thrombin Generation Is Correlated with Phenotypic Severity in Severe Hemophilia a

Disease and Treatment Knowledge Deficits in Patients with Mild and Moderate Hemophilia May Impact Transition Readiness

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Impact of Erythrocytapheresis on Endogenous Anticoagulants in Sickle Cell Disease

The Complete Type I VWD Cohort Of The Zimmerman Program For The Molecular and Clinical Biology Of VWD - Phenotypic Assignment, Mutation Frequency, and Bleeding Assessment

Epitope Specific Discrepancies Between Antibody Mediated Inhibition Of Recombinant Factor VIII and Plasma Derived Factor VIII Containing Von Willebrand Factor Affecting All Domains Of Factor VIII

Long-Term Orthopedic Effects Of Delaying Prophylaxis In Severe Hemophilia A Until Age 6 Years: Results Of The Joint Outcome Study Continuation (JOSc)

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation

Proteolytically Inactivatable Factor VIII is Less Immunogenic than Factor VIII in a Murine Hemophilia A Model.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only